Loading compound...
PPAR agonist
MURAGLITAZAR (also known as BMS-298585) is a small molecule being studied for its potential to treat type 2 diabetes and other lipid metabolism disorders. It works by acting on specific receptors in the body called PPAR alpha and PPAR gamma.
How it worksMURAGLITAZAR works by activating two specific receptors in the body: PPAR alpha and PPAR gamma, which help manage how the body uses fats and sugar.
Used for
Type 2 diabetes mellitusDiabetes mellitusDisorders of lipid metabolism
Conditions
Type 2 diabetes mellitusDiabetes mellitusDisorder of lipid metabolism
Class
PPAR agonistSmall moleculeEndocrine systemMetabolic system
How to take
This drug is currently in a research phase (Phase 3) and is not yet a standard approved treatment for these conditions based on the provided data.
Talk to your doctor
Monitor
- ·Blood sugar levels
- ·Lipid profiles
Questions to ask
- ·Is MURAGLITAZAR appropriate for my specific type of diabetes?
- ·What are the potential metabolic effects of this drug?
- ·How does this drug interact with my current lipid-lowering medications?
Pharmacokinetics
MetabolismThe drug is metabolized by P450 enzymes and UGT enzymes in humans.
Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.
